Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC-opportunities and obstacles
- PMID: 33987284
- PMCID: PMC8105855
- DOI: 10.21037/atm-2020-133
Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC-opportunities and obstacles
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-2020-133). Dr. KMF reports grants from Various competitive funding bodies, non-financial support from Industry, other from Various Universities, other from Various international funding bodies, other from UpToDate, other from Cochrane Clinical Answers, outside the submitted work. The other authors have no conflicts of interest to declare.
Comment on
-
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Transl Lung Cancer Res. 2019. PMID: 32010594 Free PMC article. Review. No abstract available.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous